Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p280 | Nutrition | ECTS2016

Effects of clinically relevant doses of vitamin A on bone in mice

Lionikaite Vikte , Gustafsson Karin , Westerlund Anna , Koskela Antti , Tukkanen Juha , Conaway H Herschel , Ohlsson Claes , Henning Petra , Lerner Ulf

Excess vitamin A has been associated with decreased cortical bone thickness and increased fracture risk. While most studies in rodents have been done using very high doses of vitamin A for a few days, we here investigate how clinically relevant doses of vitamin A, calculated from the Recommended Daily Allowance (RDA) in humans, affects the bone phenotype in mice after longer exposure.C57BL/6 mice were fed either a control diet (15 IU/g retinyl acetate), ...

ba0005p368 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Gender-different relationship between body composition and incident fracture risk in Koreans: a community-dwelling prospective cohort study

Kim Jung Hee , Hong A Ram , Choi Hyung Jin , Ku Eu Jeong , Cho Nam H , Shin Chan Soo

Low body mass index (BMI) or body weight is a well-known risk factor for osteoporosis and fragility fractures. However, the relative contribution of lean mass and fat mass on bone health, i.e. fragility fractures is inconclusive.We elucidated the relative contribution of lean and fat mass on fracture risk by group analysis in Korean men and women. This was an ongoing prospective community-dwelling cohort study at Ansung in Korea, begun in 2001. We includ...

ba0005p407 | Osteoporosis: treatment | ECTS2016

Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis

Paschalis E P , Gamsjaeger S , Hassler N , Fahrleitner-Pammer A , Dobnig H , Stepan J J , Eriksen E F , Klaushofer K

Clinical trials involving drug therapies for postmenopausal osteoporosis typically compare effects of the active drug combined with vitamin D (vit D) and calcium (Ca) vs vit D and Ca supplementation on its own. Bone strength is estimated based on the amount of bone, frequently expressed as bone mineral density determined by dual X-ray absorptiometry, and quality of bone, hardly measured in clinical practice.The purpose of the present study was to compare...

ba0001pp31 | Bone biomechanics and quality | ECTS2013

A GWAS in an extreme high bone mass population shows excess signal from genes associated with BMD in the normal population

Gregson Celia L , Leo Leo Paul J , Clark Graeme R , Smith George Davey , Brown Matthew A , Tobias Jon H , Duncan Duncan Emma L

Extreme high bone mass (HBM) may be monogenic (e.g. due to mutations in SOST or LRP5) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine the genetic cause underlying HBM in an extreme HBM population.258 unexplained HBM cases (defined as L1 Z-score ≥+3.2 plus total hip Z-score ≥+1.2, or total hip Z-score ≥+3.2 and L1 <...

ba0002oc21 | Miscellaneous | ICCBH2013

A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone

Boyce Alison M , Kelly Marilyn H , Brillante Beth A , Kushner Harvey , Wientroub Shlomo , Riminucci Mara , Bianco Paolo , Robey Pamela G , Collins Michael T

Fibrous dysplasia (FD) is a benign skeletal disease caused by activating mutations of Gsα. These mutations lead to formation of abnormal and mechanically unsound bone and fibrotic tissue. Clinical sequelae include deformity, fracture, and pain. Studies in bisphosphonates have shown improvement in bone pain and inconsistent effects on FD mineralization; however interpretation has been limited by a lack of controlled trials.Objecti...

ba0002p111 | (1) | ICCBH2013

Vitamin D status and association to bone health in 781 healthy 8–11 years old Danish school children: preliminary results from the Opus school meal study

Petersen R A , Damsgaard C T , Dalskov S , Sorensen L B , Laursen R P , Hjorth M F , Andersen R , Tetens I , Krarup H , Astrup A , Michaelsen K F , Molgaard C

Background: Low vitamin D concentrations among children and adolescents at northern latitudes are frequently observed. Also, inverse associations between 25-hydroxyvitamin D (25(OH)D) and PTH concentrations have been found in children of different ages. More studies on the link between vitamin D status and childhood bone health are needed.Objective: To evaluate the status of serum 25(OH)D in autumn and the association between 25(OH)D concentrations and b...

ba0002p114 | (1) | ICCBH2013

Association between parameters of bone mass measured by dual energy X-ray absorptiometry and quantitative ultrasound of proximal phalanges in children and adolescents with congenital adrenal hyperplasia

Goncalves Ezequiel M , Barbeta Vinicius J O , Bertapelli Fabio , Krahenbuhl Tathyane , Luiz Carlos B Ramalho , Martin Juan Eduardo Samur-San , Lemos-Marini Sofia H V , Guerra-Junior Gil

The chronic use of glucocorticoids in patients with congenital adrenal hyperplasia (CAH) may result in decreased bone mass. Therefore, using simple and accurate methods for assessing bone status in these patients could facilitate the treatment of disease. The purpose of this study was to verify the association between parameters of bone mass measured by dual energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) of proximal phalanges in children adolescents with c...

ba0003pp187 | Genetics | ECTS2014

A novel mutation in IFITM5, encoding BRIL, impairs osteoblast production of PEDF and causes atypical type VI osteogenesis imperfecta

Reich Adi , Farber Charles R , Barnes Aileen M , Becerra Patricia , Rauch Frank , Cabral Wayne A , Bae Alison , Glorieux Francis H , Clemens Thomas L , Marini Joan C

Osteogenesis imperfecta (OI) type V is caused by a unique dominant mutation (c.−14C>T) in IFITM5, which encodes BRIL, a transmembrane ifitm-like protein most strongly expressed in osteoblasts, while type VI OI is caused by recessive null mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). We identified a 25-year-old woman with severe OI, whose dermal fibroblasts and cultured osteoblasts displayed minimal secretion of PEDF, but ...